Acadia Pharmaceuticals Expects ~$1.7B Net Sales In 2028; Anticipates Phase 2 RADIANT Data Between August And October, Launches DAYBUE STIX In 2026, And Highlights Neurology Pipeline At J.P. Morgan Healthcare Conference

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

ACAD

0.00

- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID® and ~$700 million for DAYBUE®

- Top-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP-204) in Alzheimer's disease psychosis anticipated between August and October 2026

- U.S. launch of DAYBUE® STIX on a limited basis begins Q1 2026, with full launch planned Q2 2026

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.